PL3463469T3 - Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi - Google Patents
Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludziInfo
- Publication number
- PL3463469T3 PL3463469T3 PL17725086.7T PL17725086T PL3463469T3 PL 3463469 T3 PL3463469 T3 PL 3463469T3 PL 17725086 T PL17725086 T PL 17725086T PL 3463469 T3 PL3463469 T3 PL 3463469T3
- Authority
- PL
- Poland
- Prior art keywords
- ledipasvir
- sofosbuvir
- hepatitis
- humans
- treatment
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 title 1
- 229960002461 ledipasvir Drugs 0.000 title 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title 1
- 229960002063 sofosbuvir Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342787P | 2016-05-27 | 2016-05-27 | |
PCT/US2017/032282 WO2017205078A1 (en) | 2016-05-27 | 2017-05-11 | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3463469T3 true PL3463469T3 (pl) | 2024-04-22 |
Family
ID=58745467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17725086.7T PL3463469T3 (pl) | 2016-05-27 | 2017-05-11 | Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi |
Country Status (15)
Country | Link |
---|---|
US (1) | US11738013B2 (pl) |
EP (1) | EP3463469B1 (pl) |
JP (2) | JP6770098B2 (pl) |
KR (1) | KR102202984B1 (pl) |
CN (3) | CN118178444A (pl) |
AU (1) | AU2017271990B2 (pl) |
BR (1) | BR112018073858A2 (pl) |
CA (1) | CA3025633C (pl) |
EA (1) | EA201892375A1 (pl) |
ES (1) | ES2969239T3 (pl) |
MA (1) | MA45088A (pl) |
MX (1) | MX2018014377A (pl) |
PL (1) | PL3463469T3 (pl) |
SG (1) | SG11201809893WA (pl) |
WO (1) | WO2017205078A1 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
US10682369B2 (en) * | 2017-09-21 | 2020-06-16 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
KR102248165B1 (ko) | 2017-12-07 | 2021-05-06 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
EP3881850B1 (en) * | 2018-11-16 | 2024-07-17 | Tokyo Metropolitan Institute of Medical Science | Composition for inhibiting replication of hepatitis b virus |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
PL1778702T3 (pl) | 2004-07-16 | 2011-12-30 | Gilead Sciences Inc | Związki przeciwwirusowe |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TWI404537B (zh) | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
NZ568909A (en) | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
EP2043658B1 (en) | 2006-07-07 | 2012-04-25 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
AU2008271117B2 (en) | 2007-06-29 | 2013-10-24 | Gilead Sciences, Inc. | Antiviral compounds |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CN102164902B (zh) | 2008-07-08 | 2014-07-23 | 因塞特公司 | 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑 |
ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
TWI432436B (zh) | 2008-12-09 | 2014-04-01 | Gilead Sciences Inc | 類鐸受體的調節劑 |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
AP3622A (en) | 2009-05-13 | 2016-03-02 | Gilead Sciences Inc | Antiviral compounds |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
CN102781933B (zh) | 2009-08-18 | 2016-01-20 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
HUE032626T2 (en) | 2009-08-18 | 2017-10-30 | Ventirx Pharmaceuticals Inc | Toll receptor modulator substituted benzoazepines |
ES2644286T3 (es) | 2009-10-22 | 2017-11-28 | Gilead Sciences, Inc. | Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas |
WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
TWI535716B (zh) | 2010-05-31 | 2016-06-01 | Ono Pharmaceutical Co | Purine ketone derivatives |
WO2012045090A2 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Therapeutic use of a tlr agonist and combination therapy |
US20120082658A1 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the Treatment of Allergic Diseases |
KR20190140486A (ko) | 2010-11-17 | 2019-12-19 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
EP3207930A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
WO2012097173A2 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
SI3330257T1 (sl) | 2011-04-08 | 2020-07-31 | Janssen Sciences Ireland Unlimited Company | Derivati pirimidina za zdravljenje virusnih okužb |
BR112013029537B1 (pt) | 2011-05-18 | 2020-06-30 | Janssen Sciences Ireland Uc | derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende |
BR112013012091A2 (pt) | 2011-11-16 | 2019-09-10 | Gilead Sciences Inc | compostos antivirais, seu uso e composição farmacêutica |
NZ626750A (en) | 2011-11-29 | 2015-08-28 | Ono Pharmaceutical Co | Purinone derivative hydrochloride |
KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
MX357296B (es) | 2012-02-08 | 2018-07-03 | Janssen Sciences Ireland Uc | Derivados piperidinopirimidinicos para el tratamiento de infecciones viricas. |
JP6141402B2 (ja) | 2012-03-31 | 2017-06-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染の治療および予防のための新規4−メチル−ジヒドロピリミジン |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
CA2875692A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
PL2859009T3 (pl) | 2012-06-08 | 2018-03-30 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
US20140019288A1 (en) | 2012-07-13 | 2014-01-16 | Overall Parts Solutions, Inc. | Supply Chain Management System and Method |
ES2707885T3 (es) | 2012-08-10 | 2019-04-05 | Janssen Sciences Ireland Unlimited Co | Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades |
KR20210081451A (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
UA115069C2 (uk) | 2012-08-28 | 2017-09-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b |
CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
NZ706635A (en) | 2012-10-02 | 2018-08-31 | Gilead Sciences Inc | Inhibitors of histone demethylases |
US9499549B2 (en) | 2012-10-10 | 2016-11-22 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases |
JP6297055B2 (ja) | 2012-11-16 | 2018-03-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体 |
EP2928471B1 (en) | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
ES2658597T3 (es) | 2012-12-19 | 2018-03-12 | Celgene Quanticel Research, Inc. | Inhibidores de histona desmetilasa |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
US11639333B2 (en) | 2012-12-21 | 2023-05-02 | Celgene Quanticel Research, Inc | Histone demethylase inhibitors |
ES2771458T3 (es) * | 2013-01-31 | 2020-07-06 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
SG11201506717UA (en) | 2013-02-27 | 2015-09-29 | Epitherapeutics Aps | Inhibitors of histone demethylases |
WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US20140249101A1 (en) | 2013-03-04 | 2014-09-04 | Gilead Pharmasset Llc | Methods for treating hepatitis c virus infection |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
EP2968282B1 (en) | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
US20140275092A1 (en) | 2013-03-13 | 2014-09-18 | Constellation Pharmaceuticals, Inc. | Pyrazolo compounds and uses thereof |
JP6276378B2 (ja) | 2013-03-14 | 2018-02-07 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
PT2970211T (pt) | 2013-03-15 | 2017-10-31 | Quanticel Pharmaceuticals Inc | Inibidores de histona demetilase |
PT2981536T (pt) | 2013-04-03 | 2017-08-09 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b |
JP6441315B2 (ja) | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
MX2015015692A (es) | 2013-05-17 | 2016-03-04 | Hoffmann La Roche | Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b. |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
EP3068774B1 (en) | 2013-11-14 | 2019-12-25 | Novira Therapeutics Inc. | Azepane derivatives and methods of treating hepatitis b infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CN105899508B (zh) | 2014-01-30 | 2017-07-04 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物 |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
KR20160148715A (ko) | 2014-05-13 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 |
CN106573898B (zh) | 2014-08-14 | 2018-11-09 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮 |
WO2016033169A1 (en) | 2014-08-27 | 2016-03-03 | Epitherapeutics Aps | Compounds and methods for inhibiting histone demethylases |
JP6783230B2 (ja) | 2014-10-10 | 2020-11-11 | ジェネンテック, インコーポレイテッド | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
CN104546886A (zh) | 2014-12-12 | 2015-04-29 | 安徽一灵药业有限公司 | 一种雷迪帕韦与索非布韦复方包衣片制剂及其制备方法 |
-
2017
- 2017-05-11 US US16/304,824 patent/US11738013B2/en active Active
- 2017-05-11 SG SG11201809893WA patent/SG11201809893WA/en unknown
- 2017-05-11 KR KR1020187037210A patent/KR102202984B1/ko active IP Right Grant
- 2017-05-11 AU AU2017271990A patent/AU2017271990B2/en active Active
- 2017-05-11 JP JP2018561567A patent/JP6770098B2/ja active Active
- 2017-05-11 BR BR112018073858-1A patent/BR112018073858A2/pt not_active Application Discontinuation
- 2017-05-11 EA EA201892375A patent/EA201892375A1/ru unknown
- 2017-05-11 MA MA045088A patent/MA45088A/fr unknown
- 2017-05-11 ES ES17725086T patent/ES2969239T3/es active Active
- 2017-05-11 CN CN202410315443.3A patent/CN118178444A/zh active Pending
- 2017-05-11 WO PCT/US2017/032282 patent/WO2017205078A1/en unknown
- 2017-05-11 EP EP17725086.7A patent/EP3463469B1/en active Active
- 2017-05-11 CN CN201780039972.3A patent/CN109414508A/zh active Pending
- 2017-05-11 CA CA3025633A patent/CA3025633C/en active Active
- 2017-05-11 PL PL17725086.7T patent/PL3463469T3/pl unknown
- 2017-05-11 CN CN202410315442.9A patent/CN118178652A/zh active Pending
- 2017-05-11 MX MX2018014377A patent/MX2018014377A/es unknown
-
2020
- 2020-09-24 JP JP2020159362A patent/JP2020203947A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102202984B1 (ko) | 2021-01-13 |
BR112018073858A2 (pt) | 2019-02-26 |
US20220117952A1 (en) | 2022-04-21 |
CA3025633C (en) | 2021-02-23 |
JP2020203947A (ja) | 2020-12-24 |
CN109414508A (zh) | 2019-03-01 |
CA3025633A1 (en) | 2017-11-30 |
CN118178444A (zh) | 2024-06-14 |
EP3463469C0 (en) | 2023-12-13 |
WO2017205078A1 (en) | 2017-11-30 |
MX2018014377A (es) | 2019-03-14 |
AU2017271990A1 (en) | 2018-11-29 |
CN118178652A (zh) | 2024-06-14 |
JP6770098B2 (ja) | 2020-10-14 |
KR20190010631A (ko) | 2019-01-30 |
ES2969239T3 (es) | 2024-05-17 |
MA45088A (fr) | 2019-04-10 |
SG11201809893WA (en) | 2018-12-28 |
AU2017271990B2 (en) | 2019-12-19 |
EP3463469B1 (en) | 2023-12-13 |
JP2019519526A (ja) | 2019-07-11 |
EA201892375A1 (ru) | 2019-08-30 |
US11738013B2 (en) | 2023-08-29 |
EP3463469A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251219A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的6,7-二氫吡啶並[2,1-a]酞嗪-2-酮類化合物 | |
HRP20190352T1 (hr) | Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b | |
IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
HK1223931A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物 | |
HK1219480A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的 -橋連的雜芳基二氫嘧啶 | |
ZA201705633B (en) | A new quinoline derivative for use in the treatment and prevention of viral infections | |
HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
IL281277A (en) | Preparations and methods for treating viral infections | |
IL262579A (en) | Compounds and methods for treating viral infection in shrimp | |
IL263368A (en) | Prevention and treatment of viral infections | |
HK1252343A1 (zh) | 用於治療病毒感染的組合物和方法 | |
PL3463469T3 (pl) | Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi | |
PL3407890T3 (pl) | Preparat farmaceutyczny i jego zastosowanie w leczeniu wirusowego zapalenia krtani | |
EP3261439A4 (en) | METHOD AND MATERIALS FOR TREATING HUMAN IMMUNE WEAKAGE VIRUS INFECTIONS | |
HUE045242T2 (hu) | Vírusfertõzések megelõzésére és terápiájára szánt ágens | |
IL253418A0 (en) | Nisin-based compounds and their use in the treatment of bacterial infections | |
ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer | |
TH1601001266A (th) | วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b |